Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Rementer, Cameron [VerfasserIn]   i
 Yavirach, Apichai [VerfasserIn]   i
 Buranaphatthana, Worakanya [VerfasserIn]   i
 Walczak, Philip A. [VerfasserIn]   i
 Speer, Mei [VerfasserIn]   i
 Pierce, Kat [VerfasserIn]   i
 Dharmarajan, Subramanian [VerfasserIn]   i
 Leber, Elizabeth [VerfasserIn]   i
 Sangiorzan, Bruce [VerfasserIn]   i
 Bain, Steven [VerfasserIn]   i
 Scatena, Marta [VerfasserIn]   i
 Blümke, Alexander Felix [VerfasserIn]   i
 Giachelli, Cecilia M. [VerfasserIn]   i
Titel:Engineered myeloid precursors differentiate into osteoclasts and resorb heterotopic ossification in mice
Verf.angabe:Cameron Rementer, Apichai Yavirach, Worakanya Buranaphatthana, Philip A. Walczak, Mei Speer, Kat Pierce, Subramanian Dharmarajan, Elizabeth Leber, Bruce Sangiorzan, Steven Bain, Marta Scatena, Alexander Blümke and Cecilia M. Giachelli
E-Jahr:2024
Jahr:22 November 2024
Umfang:12 S.
Fussnoten:Gesehen am 16.04.2025
Titel Quelle:Enthalten in: Frontiers in Bioengineering and Biotechnology
Ort Quelle:Lausanne : Frontiers Media, 2013
Jahr Quelle:2024
Band/Heft Quelle:12(2024), Seite 1-12
ISSN Quelle:2296-4185
Abstract:Introduction - Heterotopic ossification (HO) occurs following orthopedic trauma, spinal cord injuries, brain trauma and limb amputations. Once symptomatic, HO causes pain, limited mobility and decreased quality of life. Current treatments are limited and have significant complications with high recurrence rates, underscoring the need for improved therapeutic interventions. Osteoclasts (OCs) are physiological bone resorptive cells that secrete enzymes and protons to degrade bone. - - Methods - In this study, we describe the use of genetically engineered OCs as a novel cell therapy approach to treat HO. Inducible, engineered myeloid precursors (iRANK cells) treated with a chemical inducer of dimerization (CID) differentiated into TRAP+ multinucleated OCs and resorbed mineralized tissues in vitro. - - Results - In vivo, BMP-2-induced murine HO lesions were significantly regressed following treatment using iRANK cells with concomitant systemic administration of CID. Moreover, many OCs were TRAP+, MMP9+, and GFP+, indicating that they differentiated from delivered iRANK cells. - - Discussion - In summary, these data con rm the ability of engineered myeloid precursors to differentiate into OCs and resorb HO in vivo paving the way for OC delivery as a promising approach for HO treatment.
DOI:doi:10.3389/fbioe.2024.1491962
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.3389/fbioe.2024.1491962
 Volltext: https://www.frontiersin.orghttps://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe. ...
 DOI: https://doi.org/10.3389/fbioe.2024.1491962
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Chemical inducer of dimerization
 Engineered Osteoclasts
 heterotopic ossification
 Osteoclasts
 Rank
 Resorption
K10plus-PPN:1923046055
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69331670   QR-Code
zum Seitenanfang